Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of unusually large options trading on Wednesday. Stock investors purchased 1,276 put options on the stock. This is an increase of approximately 1,139% compared to the average daily volume of 103 put options.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 130,000 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $18.45, for a total value of $2,398,500.00. Following the completion of the sale, the insider now owns 791,666 shares of the company’s stock, valued at $14,606,237.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Julie Mchugh sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $19.10, for a total value of $28,650.00. Following the completion of the sale, the director now directly owns 91,131 shares of the company’s stock, valued at approximately $1,740,602.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,339 shares of company stock valued at $4,475,466. 7.63% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $186,000. A.R.T. Advisors LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $208,000. V Wealth Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $258,000. PNC Financial Services Group Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 17,621.9% during the second quarter. PNC Financial Services Group Inc. now owns 17,013 shares of the biotechnology company’s stock valued at $325,000 after purchasing an additional 16,917 shares during the period. Finally, LPL Financial LLC boosted its stake in shares of Ironwood Pharmaceuticals by 16.3% during the first quarter. LPL Financial LLC now owns 21,160 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 2,959 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

IRWD has been the subject of several research reports. Cowen reaffirmed a “market perform” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, July 18th. HC Wainwright initiated coverage on Ironwood Pharmaceuticals in a research note on Monday, July 23rd. They issued a “sell” rating and a $12.50 target price for the company. BidaskClub lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 26th. Wells Fargo & Co set a $23.00 target price on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Finally, ValuEngine lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. Four research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus target price of $17.35.

NASDAQ:IRWD opened at $11.92 on Thursday. The company has a market cap of $1.96 billion, a PE ratio of -12.82 and a beta of 1.33. Ironwood Pharmaceuticals has a fifty-two week low of $11.86 and a fifty-two week high of $21.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.24). The firm had revenue of $68.69 million during the quarter, compared to analysts’ expectations of $93.48 million. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.18) earnings per share. As a group, sell-side analysts forecast that Ironwood Pharmaceuticals will post -0.73 EPS for the current year.

WARNING: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/08/investors-purchase-large-volume-of-ironwood-pharmaceuticals-put-options-irwd.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Featured Story: How to Invest in Growth Stocks

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.